Phyton Biotech showcases plant cell fermentation technology at world’s largest pharmaceutical industry trade show

Phyton Biotech recently attended CPhI Worldwide in Madrid, Spain, where we showcased our award-winning and environmentally responsible Plant Cell Fermentation (PCF ®) technology for the production of paclitaxel and docetaxel and other high-value phytochemicals.

CPhI Worldwide is the largest pharmaceutical industry trade show, bringing together pharmaceutical industry suppliers and buyers from all over the world. The event drew more than 45,000 pharma professionals and 2,500 exhibitors.

At CPhI, Phyton Biotech focused its discussions with current and potential clients and buyers on how its proprietary technology offers a time, risk and cost-balanced pathway to commercially viable production processes, overcoming limitations and drawbacks often experienced with traditional plant extraction and chemical synthesis.

“This year, Phyton Biotech had a strong visible presence at the trade show with our branded exhibition booth highlighting how PCF ® can be successfully implemented for the development and commercialization of plant-based molecules, and recombinant products, serving the pharmaceutical, Traditional Chinese Herbal Medicine (TCM), Cosmetic, Agricultural and Food Ingredient industries,” says Colin Marr, President of Phyton Biotech.  “Our business development team was kept busy meeting with multiple interested parties throughout the three-day trade show.”

On the first day of CPhI, Dr. Gilbert Gorr, Phyton’s Chief Scientific Officer, presented “Plant cell culture – A sustainable way to ensure and improve your supply chain”. The following is the abstract from Dr. Gorr’s presentation:

Plants have been considered as a source of natural substances for ages. Plant compounds are most famous for medical applications – as lead structures, precursors or API. However, supply of compounds from natural harvest can be limited by numerous factors i.e. batch to batch variations, destruction of the source and low product content.

In addition, access to plant material can be restricted through political or regulatory requirements. Extraction and purification of compounds from harvested plant material often require huge volumes of hazardous and toxic solvents. In many cases the complexity of secondary metabolites precludes chemical synthesis on a reasonable commercial basis, too. 

Plant cell fermentation (PCF®) – the production of plant-derived compounds in a bioreactor environment – provides an attractive supply solution. In addition to solving above described supply issues production through plant cell culture in bioreactors can improve safe handling and allows prompt adaption of scale according to the demand for the product.

Plant cell culture and its commercial applications were presented in the context of sustainability and “green chemistry” based on several examples – from development projects to applied manufacturing.

For queries about Phyton Biotech, our revolutionary PCF ® technology or Dr. Gilbert Gorr’s talk at CPhI Worldwide, please contact Kai Schütte. For more information, please visit our website.